All In Biotech

Drug Trial Radar · NCT03040973

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

An Open-label, Multi-center, Global, Rollover Study for Patients Who Have Previously Been Treated With Capmatinib (INC280) as Monotherapy or in Combination in a Novartis Sponsored Trial.

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

29

Actual

Start

Jul 4, 2017

Primary completion

Jul 30, 2027

Study completion Jul 30, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess long-term safety and provide continued study treatment access to eligible participants who are judged by the Investigator to benefit from continued treatment with capmatinib monotherapy or in combination with other treatments or with the combination treatment alone in a Novartis sponsored study

Conditions

  • Advanced Solid Tumors Which Are cMET-dependent

Interventions

  • CapmatinibDrug

    Tablet for oral use; 150 mg, 200 mg; twice a day

  • NazartinibDrug

    Capsule for oral use; 25 mg, 50 mg; once a day

  • GefitinibDrug

    tablets for oral use; 250mg; once a day

  • OsimertinibDrug

    Tablets for oral use; 40 mg, 80 mg; once a day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events as a Measure of Safety and TolerabilityTime frame: Day 1 up to 10 years, assessed every 12 weeks

Locations

15 sites in 11 countries. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Edmonton, Alberta, Canada

  • Novartis Investigative Site

    Shanghai, Shanghai Municipality, China

  • Novartis Investigative Site

    Kunming, Yunnan, China

  • Novartis Investigative Site

    Copenhagen, Denmark

  • Novartis Investigative Site

    Dijon, Cote D Or, France

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, Germany

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Perugia, PG, Italy

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.